-
Product Name
Anti-CPE antibody
- Documents
-
Description
Rabbit Polyclonal to Human CPE
-
Tested applications
WB, IHC-P
-
Species reactivity
Human Carboxypeptidase E/CPE
-
Alternative names
Carboxypeptidase E antibody; Carboxypeptidase E antibody; Cpe antibody; CPE antibody; CPH antibody; Cph1 antibody; Cph-1 antibody; fat antibody; MGC7101 antibody; R74677 antibody; FAT antibody; CPH antibody; Cph1 antibody; Cph-1 antibody; R74677 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with purified, recombinant Human Carboxypeptidase E/CPE . Carboxypeptidase E/CPE specific IgG was purified by Human Carboxypeptidase E/CPE affinity chromatography.
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
WB: 5-20 μg/ml
IHC-P: 0.1-1 μg/mL
-
Validations
Human Carboxypeptidase E/CPE Western blot (WB) 15832
Human Carboxypeptidase E/CPE Immunohistochemistry(IHC) 15833
-
Background
Human carboxypeptidase E (CPE), also known as Carboxypeptidase H, is a peripheral membrane protein and a zinc metallocarboxypeptidase, and the conversion of proCPE into CPE occurs primarily in secretory vesicles. The active form of CPE cleaves C-terminal amino acid residues of the peptide, and is thus involved in the biosynthesis of peptide hormones and neurotransmitters including insulin, enkephalin, etc. The enzymatic activity is enhanced by millimolar concentrations of Co2+. It has also been proposed that membrane-associated carboxypeptidase E acts as a sorting receptor for targeting regulated secretory proteins which are mostly prohormones and neuropeptides in the trans-Golgi network of the pituitary and in secretory granules into the secretory pathway.Its interaction with glycosphingolipid-cholesterol rafts at the TGN facilitates the targeting. Mutations in this gene are implicated in type I I diabetes due to impaired glucose clearance and insulin resistance.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"